List of Tables
Table 1: Biosimilars Approval Pathways in the US and Europe, Medicare Formulary Coverage for Top-Selling Biologics
Table 2: Biosimilars Approval Pathways in the US and Europe, Global, Market Forecasts, ($m), 2009–2016
Table 3: Biosimilars Approval Pathways in the US and Europe, the US, Market Forecasts, ($m), 2009–2016
Table 4: Biosimilars Approval Pathways in the US and Europe, Europe, Market Forecasts, ($m), 2009–2016
Table 5: Biosimilars Approval Pathways in the US and Europe, Japan, Market Forecasts, ($m), 2009–2016
Table 6: Biosimilars Approval Pathways in the US and Europe, Global, hGH Biosimilars Market Forecasts, ($m), 2009–2016
Table 7: Biosimilars Approval Pathways in the US and Europe, Global, EPO Biosimilars Market Forecasts, ($m), 2009–2016
Table 8: Biosimilars Approval Pathways in the US and Europe, Global, G-CSF Biosimilars Market Forecasts, ($m), 2009–2016
Table 9: Biosimilars Approval Pathways in the US and Europe, Global, Interferon alfa Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Table 10: Biosimilars Approval Pathways in the US and Europe, Global, Interferon-beta Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Table 11: Biosimilars Approval Pathways in the US and Europe, Global, Insulin and Insulin Analogs Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Table 12: Biosimilars Approval Pathways in the US and Europe, Global, TNF alfa Inhibitor Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Table 13: Biosimilars Approval Pathways in the US and Europe, Global, Monoclonal Antibodies Against Cancer Biosimilar Market Opportunity Analysis, ($m), 2009–2016
Table 14: Biosimilars Approval Pathways in the US and Europe, Cost-Sharing Practices by Health Insurers in the US, 2009
Table 15: Biosimilars Approval Pathways in the US and Europe, Comparison for a Biosimilar, 2010
Table 16: Biosimilars Approval Pathways in the US and Europe, Patent Expiry for Major Biologic Drugs, 2010–2016
Table 17: Biosimilars Approval Pathways in the US and Europe, Costs of Development, Manufacturing and Approval of Biosimilars By Cell Culture Type, ($m), 2010
Table 18: Biosimilars Approval Pathways in the US and Europe, Europe, Existing Guidelines for Biosimilars, 2010
Table 19: Biosimilars Approval Pathways in the US and Europe, Biosimilar Approvals, 2010
Table 20: Biosimilars Approval Pathways in the US and Europe, Europe, Applications Rejected or Withdrawn, 2010